Several ongoing clinical trials (NCT04732494, NCT04140500, NCT03708328) combining anti-PD-1 and anti-TIGIT/TIM/LAG-3 treatment as novel immunotherapies are expected to provide better prognosis for ESCC patients. Here, PDCD1 is linked to esophageal squamous cell carcinoma.